Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ethyl Propionate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SI | P14410 | 1/20 | 0.48 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | WRN | Q14191 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethyl Propionate SCHEMBL104601 | 0.94 | MGAM (0.43) | MGAMGAASIMGAM2TDP1 | |
| Ethyl Propionate SCHEMBL28313478 | 0.88 | GAA (0.55) | MGAMGAASIMGAM2ALDH1A1 | |
| Ethyl Propionate SCHEMBL4580029 | 0.87 | MGAM (0.38) | MGAMGAASIMGAM2TDP1 | |
| Ethyl Propionate SCHEMBL4580712 | 0.84 | GAA (0.39) | MGAMGAASIMGAM2TDP1 | |
| Propylene Glycol SCHEMBL7585402 | 0.83 | TDP1 (0.53) | TDP1ALDH1A1NAAALMNAHSD17B10 | |
| Ethyl Propionate SCHEMBL8016576 | 0.83 | TDP1 (0.41) | MGAMGAASIMGAM2TDP1 | |
| Ethyl Propionate SCHEMBL8162256 | 0.83 | GAA (0.60) | MGAMGAASIMGAM2ALDH1A1 | |
| Propylene Glycol SCHEMBL3342302 | 0.83 | MAPT (0.47) | MGAMGAASIMGAM2TDP1 | |
| Propylene Glycol SCHEMBL28409524 | 0.83 | NAAA (0.50) | GAATDP1ALDH1A1NAAALMNA | |
| Malonic Acid Diethyl Ester SCHEMBL7535224 | 0.83 | GAA (0.62) | MGAMGAASIMGAM2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 709 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3543679-B1 | METHOD FOR ANALYZING DIFFUSION COEFFICIENT OF SOLVENT MOLECULES IN POLYMER MATERIAL | LG CHEMICAL LTD (KR) | 2025-10-01 | — | — | EP | claimed |
| US-12428737-B2 | Cleaning liquid used for cleaning metal resists, and cleaning method using cleaning liquid | TOKYO OHKA KOGYO CO., LTD. (JP) | 2025-09-30 | — | — | US | claimed |
| US-12428611-B2 | Cleaning liquid used for cleaning metal resists, and cleaning method using cleaning liquid | TOKYO OHKA KOGYO CO., LTD. (JP) | 2025-09-30 | — | — | US | claimed |
| EP-4586999-A1 | PHARMACEUTICAL COMPOSITIONS OF ROFLUMILAST AND SOLVENTS CAPABLE OF DISSOLVING HIGH AMOUNTS OF THE DRUG | Arcutis Biotherapeutics, Inc. (US) | 2025-07-23 | — | — | EP | claimed |
| US-20250144084-A1 | PHARMACEUTICAL COMPOSITIONS OF ROFLUMILAST AND SOLVENTS CAPABLE OF DISSOLVING HIGH AMOUNTS OF THE DRUG | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2025-05-08 | — | — | US | claimed |
| US-12144802-B2 | Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2024-11-19 | — | — | US | claimed |
| EP-3674389-B1 | SOLVENT COMPOSITION, CLEANING METHOD, METHOD FOR PRODUCING COATED SUBSTRATE, AND HEAT TRANSFER MEDIUM | AGC INC (JP) | 2024-05-08 | — | — | EP | claimed |
| US-20240108609-A1 | PHARMACEUTICAL COMPOSITIONS OF ROFLUMILAST AND SOLVENTS CAPABLE OF DISSOLVING HIGH AMOUNTS OF THE DRUG | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2024-04-04 | — | — | US | claimed |
| WO-2024058848-A1 | PHARMACEUTICAL COMPOSITIONS OF ROFLUMILAST AND SOLVENTS CAPABLE OF DISSOLVING HIGH AMOUNTS OF THE DRUG | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2024-03-21 | — | — | WO | claimed |
| US-20230367223-A1 | SUBSTRATE PROCESSING COMPOSITION AND SUBSTRATE PROCESSING METHOD USING THE SAME | SK INC. (KR) | 2023-11-16 | — | — | US | claimed |
| US-6680263-B2 | Method for applying a photoresist layer to a substrate having a preexisting topology | SANDIA NATIONAL LABORATORIES | 2004-01-20 | — | — | US | claimed |
| WO-2003075339-A1 | B-STAGEABLE UNDERFILL ENCAPSULANT AND METHOD FOR ITS APPLICATION | NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING CORPORATION (US) | 2003-09-12 | — | — | WO | claimed |
| WO-2003075338-A1 | UNDERFILL ENCAPSULANT FOR WAFER PACKAGING AND METHOD FOR ITS APPLICATION | NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING CORPORATION (US) | 2003-09-12 | — | — | WO | claimed |
| US-20030171456-A1 | Underfill encapsulant for wafer packaging and method for its application | HENKEL AG & CO. KGAA (DE) | 2003-09-11 | — | — | US | claimed |
| US-20030164555-A1 | B-stageable underfill encapsulant and method for its application | NATIONAL STARCH AND CHEMICAL INVESTMENT | 2003-09-04 | — | — | US | claimed |
| US-20030152875-A1 | Method for applying a photoresist layer to a substrate having a preexisting topology | NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC | 2003-08-14 | — | — | US | claimed |
| EP-0851295-B1 | Process for the fabrication of microstructures by multilayer conformation of a photosensitive resin et microstructures obtained therewith | MIMOTEC SA (CH) | 2001-10-24 | — | — | EP | claimed |
| EP-0754975-B1 | Process of reducing trace levels of metal impurities from resist components | OLIN CORP (US) | 1999-09-01 | — | — | EP | claimed |
| US-5618655-A | Process of reducing trace levels of metal impurities from resist components | OLIN CORPORATION (US) | 1997-04-08 | — | — | US | claimed |
| EP-0754975-A2 | Process of reducing trace levels of metal impurities from resist components | OLIN CORPORATION (US) | 1997-01-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12144802-B2 | Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug | MMP1, MMP13, PLAT | MGAM 549/4885GAA 1407/4885SI 345/4885 |
| US-20240108609-A1 | PHARMACEUTICAL COMPOSITIONS OF ROFLUMILAST AND SOLVENTS CAPABLE OF DISSOLVING HIGH AMOUNTS OF THE DRUG | MMP1, MMP13, PLAT | MGAM 549/4885GAA 1407/4885SI 345/4885 |
| US-20250144084-A1 | PHARMACEUTICAL COMPOSITIONS OF ROFLUMILAST AND SOLVENTS CAPABLE OF DISSOLVING HIGH AMOUNTS OF THE DRUG | MMP1, MMP13, PLAT | MGAM 549/4885GAA 1407/4885SI 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.